Supplemental Digital Content

Supplementary Figures

Supplementary Fig. 1 Study design. R, randomization; S, screening; T, taper (non-responding patients). *Only for non-responders at Visit 4 and/or Visit 6. †Only for patients with unsatisfactory tolerability at Visit 7.

Pre-Treatment Phase	;	Double-Blind Treatment Phase							
Wash-outTrazodone OAD (from 300 mg/day up to 375/450 mg/day)TSRVenlafaxine XR (from 75 mg/day up to 150/225 mg/day)T									
L			1						
Visit (V) 1 D-n	V2 D0	V3 D7	V4 D21	V5* D28	V6 D35	V7* D42	V8 [†] D49	V9 D56	V10 D63/70/77